CANCER MONOCLONAL ANTIBODIES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Key Developments

• On August 17, 2024, Cizzle Biotechnology, a diagnostics company focused on developing a cost effective biomarker test to help detect early-stage lung cancer, announced a strategic agreement with BBI Solutions, a biotechnology company based in the U.K., to supply its first order of commercial propriety monoclonal antibodies. This agreement is a significant milestone for Cizzle Biotechnology to commercialize its cost-effective biomarker test for early-stage lung cancer detection.
• On February 28, 2024, AbbVie Inc., a global pharmaceutical firm, and OSE Immunotherapeutics SA, a clinical-stage immunotherapy company, announced a strategic partnership to develop OSE-230, a monoclonal antibody targeted to treat chronic and severe inflammation that is currently in pre-clinical development. OSE-230 is a first-in-class monoclonal antibody that activates ChemR23, a GPCR target. ChemR23 activation may provide a unique strategy for resolving chronic inflammation by altering macrophage and neutrophil activity.
• In October 2023, Bio-Rad Laboratories, Inc., a life science company, extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of six antibodies specific to dupilumab (Dupixent) and the addition of new evolocumab (Repatha), ipilimumab (Yervoy), and secukinumab (Cosentyx) antibodies
• In February 2022, Rockland Immunochemicals, Inc., a global biotechnology company, announced that it had completed the acquisition of antibodies-online GmbH (antibodies-online), part of Rockland Immunochemicals, Inc., one of the leading vendor-independent marketplaces for research reagents, especially antibodies, proteins, and ELISA kits to accelerate and enable scientific discovery and development of therapies and diagnostics.